Medicare ineligible PLHIV in Australia

NAPWHA, May 2019

This NAPWHA report is an analysis drawing together several years’ worth of data from the main pharmaceutical industry suppliers of compassionate access antiretroviral (ARV) therapy in Australia and combines this with, for the first time, data from the State and Territory jurisdictions to produce the most accurate estimate to-date of the number of Medicare ineligible PLHIV in Australia. It comes with recommendations for systemic improvements.

It’s time to lift the restrictions on medical abortion in Australia – Professor Caroline de Costa

The Conversation, April 1, 2019 6.13am AEDT

Over the past thirteen years, many Australian women have used the drug mifepristone (RU486) to bring about a medical abortion.

Rather than undergoing a surgical abortion in a clinic or hospital operating theatre, a medical abortion is induced by taking drugs prescribed by a doctor.

But while mifepristone has been available in Australia since 2006, only some women, in some parts of the country, are able to access it. Professor Caroline de Costa argues in the Medical Journal of Australia that this needs to change.

Pelvic mesh implant patients want answers from Senate report

ABC 730 report, 26/3/2018

A steady stream of Australian women with pelvic mesh implants have spent tens of thousands of dollars flying to a clinic in Missouri to have their implants removed, claiming they have suffered major side-effects from the implants used to treat prolapse and incontinence.

More than 35 Australian women have made the journey to the same practitioner because, they say, they don’t have faith in Australian surgeons to carry out a full removal of their implant.

The claim that Australia does not have the expertise is rejected by both the Australian Medical Association (AMA) and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG).

 

 

Essure contraceptive device: Hazard Alert from TGA

Therapeutic Goods Administration, August 30, 2017

Consumers and health professionals are advised that Australasian Medical and Science Ltd (AMSL), in consultation with the TGA, has issued a hazard alert for Essure. AMSL is also recallingunused stock and withdrawing the device from the Australian market.

New class of antibiotic raises hopes for urgently-needed gonorrhoea drug

The Guardian, Tuesday 8 August 2017 

A new class of antibiotic has been found to work in the lab against the sexually transmitted infection gonorrhoea, which can cause infertility and damage to babies and is fast becoming resistant to all existing drugs.

Although it is early days, because the antibiotic has yet to be tried in animals or humans, researchers say they are excited by its potential.

The battle over Essure

The Washington Post, Published on July 26, 2017

Nobody can say exactly how many women have had Essure implanted since the device went on the market in 2002. Bayer, which is headquartered in Germany, says that more than 750,000 devices have been sold worldwide and that sales “continue to grow.” 

In recent years, the [US] Food and Drug Administration has received more than 16,000 adverse-event reports about Essure. These are official reports about symptoms, hospitalizations or diagnoses that patients, doctors, hospitals or a device manufacturer believe are associated with a device.

“It seems every two or three years we have another controversy in women’s health,” says Steve Xu, a health-­policy researcher and Northwestern University dermatology resident.